Health

U.S. set to begin sharing its entire stock of AstraZeneca-Oxford COVID-19 vaccines

The White House tells The Associated Press that the U.S. will begin sharing its entire stock of COVID-19 vaccines from AstraZeneca once the vaccine clears federal safety reviews, with 60 million doses expected to be available for export in the coming months.

60 million doses expected to be available for export in coming months, White House says

U.S. President Joe Biden while touring a vaccine manufacturing plant in mid-February. The White House says the U.S. will begin sharing its entire stock of COVID-19 vaccines from AstraZeneca once the vaccine clears federal safety reviews. (Tom Brenner
/Reuters)

The U.S. will begin sharing its entire pipeline of vaccines from AstraZeneca-Oxford once the COVID-19 vaccine clears federal safety reviews, the White House told The Associated Press on Monday — with as many as 60 million doses expected to be available for export in the coming months.

The move greatly expands on the Biden administration's action last month to share about four million doses of the vaccine with Canada and Mexico.

The AstraZeneca vaccine is widely in use around the world, including here in Canada, but is not yet authorized by the U.S. Food and Drug Administration.

The White House is increasingly confident in the supply of the three vaccines being administered in the U.S., particularly following the restart of the single-dose Johnson & Johnson shot over the weekend.

The U.S. also has been under mounting pressure in recent weeks to share more of its vaccine supply with the world, as nations like India experience devastating surges of the virus and others struggle to access doses needed to protect their most vulnerable populations.

"Given the strong portfolio of vaccines that the U.S. already has and that have been authorized by the FDA, and given that the AstraZeneca vaccine is not authorized for use in the U.S., we do not need to use the AstraZeneca vaccine here during the next several months," said White House COVID-19 coordinator Jeff Zients.

"Therefore, the U.S. is looking at options to share the AstraZeneca doses with other countries as they become available."

U.S. has yet to finalize where doses will go

More than three million people worldwide have died of COVID-19, including more than 572,000 in the U.S.

The United States has vaccinated more than half of its adult population with at least one dose of its three authorized vaccines from Pfizer, Moderna and Johnson & Johnson, and it expects to have enough supply for its entire population by early summer

About 10 million doses of the AstraZeneca vaccine have been produced but have yet to pass review by the FDA to "meet its expectations for product quality," Zients said, noting the U.S. regulator is recognized as the "gold standard" for safety around the world. That process could be completed in the next several weeks.

About 50 million more doses are in various stages of production and could be available to ship in May and June pending FDA sign-off.

The U.S. has yet to finalize where the AstraZeneca doses will go, Zients said. Both Canada and Mexico have asked the Biden administration to share more doses, while dozens of other countries are looking to access supplies of the vaccine.

The AstraZeneca doses will be donated by the U.S. government, which has contracted with the company for a total of 300 million doses — though the company has faced production issues.

AstraZeneca's doses in the U.S. were produced at an Emergent BioSolutions plant in Baltimore that has come under increased regulatory and public scrutiny after botching batches of the J&J vaccine.

The U.S. pressed J&J to take over the plant and, as part of the effort to ensure the quality of newly produced vaccines, directed the facility to stop making the AstraZeneca shot. AstraZeneca is still looking to identify a new U.S. production facility for its future doses.

AstraZeneca's vaccine was expected initially to be the first to receive federal emergency authorization, and the U.S. government ordered enough for 150 million Americans before issues with the vaccine's clinical trial held up clearance.

The company's 30,000-person U.S. trial didn't complete enrolment until January, and it has still not filed for an emergency-use authorization with the FDA.

Add some “good” to your morning and evening.

A variety of newsletters you'll love, delivered straight to you.

Sign up now

Comments

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Become a CBC Member

Join the conversationCreate account

Already have an account?

now